Catherine Ann Shu, MD

Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.

Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.

Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.

Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.